Mark Aimone brings over 30 years of CMC, Supply Chain and Strategic Sourcing experience, including strong operational leadership within R&D and manufacturing organizations.
He will have responsibility for building and leading EvolveImmune’s CMC development function and manufacturing operations. Before joining EV, Mark was Vice President at Alexion-AstraZeneca Rare Disease Business Unit where he built and led the CMC Leadership group. In addition, Mark had overall responsibility for the rare disease clinical supply chain including internal and external (CMO) manufacturing, packaging, and distribution operations. Mark also had overall budget responsibility for all CMC operations.
He joined Alexion in 2016 and played a pivotal role in bringing Ultomiris (ravulizumab, humanized monoclonal antibody complement inhibitor) into Phase 3 and approval in 2018. At Alexion/AZ he chaired cross functional CMC governance and was a senior member of the Product Development and Clinical Supply Leadership team within Research and Development.
Prior to joining Alexion in 2016, Mark held positions of increasing responsibility at Pfizer in Groton, CT. Mark had responsibility for the CMC leadership groups for both Primary and Specialty Care at Pfizer and held clinical supply, strategic sourcing and technology transfer positions over his 20 year career. Mark received his Bachelor’s degree from Villanova University and his MBA from Rensselaer Polytechnic Institute.